ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.

Clemens Krepler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.